These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9264767)

  • 1. [Effectiveness and tolerance of three month sustained release leuprorelin in the treatment of metastatic prostatic cancer (comparative, randomized, multicentric study].
    Zerbib M; Lucas C; Leblanc V
    Prog Urol; 1997 Apr; 7(2):246-53. PubMed ID: 9264767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
    Abbou CC; Lucas C; Leblanc V
    Prog Urol; 1997 Dec; 7(6):984-95. PubMed ID: 9490144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe.
    Tunn UW; Wiedey K
    Prostate Cancer Prostatic Dis; 2009; 12(1):83-7. PubMed ID: 19030021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.
    Berges R; Bello U
    Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S; Lawrentschuk N; Grills RJ; Neerhut G
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
    Crawford ED; Sartor O; Chu F; Perez R; Karlin G; Garrett JS
    J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation therapy.
    Zuckerman JM; Eure G; Malcolm J; Currie L; Given R
    Urology; 2014 Mar; 83(3):670-4. PubMed ID: 24360065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
    Gittelman M; Pommerville PJ; Persson BE; Jensen JK; Olesen TK;
    J Urol; 2008 Nov; 180(5):1986-92. PubMed ID: 18801505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate.
    Khan MS; O'Brien A
    Urol Int; 1998; 60(1):33-40. PubMed ID: 9519419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
    Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
    Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of metastatic prostatic cancer with monthly injections of leuprolide acetate depot].
    Jiménez Cruz JF; Vera Donoso CD; Iborra I; Solsona E; Forner E; Villavicencio H; Díaz C; González C; Rioja L; Pertusa C
    Actas Urol Esp; 1994 Feb; 18(2):90-3. PubMed ID: 7976707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical evaluation of enantone in the treatment of prostate cancer].
    Zhang L; Tao D; Wang S
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):218-20. PubMed ID: 10920902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer.
    Perez-Marreno R; Chu FM; Gleason D; Loizides E; Wachs B; Tyler RC
    Clin Ther; 2002 Nov; 24(11):1902-14. PubMed ID: 12501882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.